

## Background

- Harris G. Researchers Find Study of Medical Marijuana Discouraged. *New York Times* 2010. Available from: [http://www.nytimes.com/2010/01/19/health/policy/19marijuana.html?\\_r=1](http://www.nytimes.com/2010/01/19/health/policy/19marijuana.html?_r=1) Accessed on: November 25, 2015.
- National Institute on Drug Abuse, National Institute of Health. Marijuana Research at NIDA. 2014 Jan; drugabuse.gov. Available from: <http://www.drugabuse.gov/drugs-abuse/marijuana/marijuana-research-nida> Accessed on: November 25, 2015.
- National Institute on Drug Abuse, National Institute of Health. NIDA's Role in Providing Marijuana Research. 2015. Available from: <http://www.drugabuse.gov/drugs-abuse/marijuana/nidas-role-in-providing-marijuana-research>. Accessed on: December 7, 2015.
- National Institute of Health, U.S. Library of Medicine. Marijuana. 2015 Nov; MedlinePlus. Available from: <https://www.nlm.nih.gov/medlineplus/marijuana.html#cat79>. Accessed on: November 25, 2015.

## Chronic Pain

- Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology*. 2007;68(7):515-521.
- Berman J, the Sativex Spinal Cord Injury Study Group, Bosworth T, Guy G, Stott C. Sativex® in the Treatment of Central Neuropathic Pain due to Spinal Cord Injury: A Randomised Controlled Study. 2007. Available from: [http://www.cannabis-med.org/studies/ww\\_en\\_db\\_study\\_show.php?s\\_id=211](http://www.cannabis-med.org/studies/ww_en_db_study_show.php?s_id=211). Accessed on: December 3, 2015
- Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *NEuropsychopharmacology*. 2009;34(3):672-680.
- GW Pharmaceuticals Ltd. A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy. 2008.
- Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. *Diabetes Care*. 2010;33(1):128-130.
- Wallace M, Atkinson J, Gouaux B, Marcotte T, Umlauf A. Effect of smoked cannabis on painful diabetic peripheral neuropathy. *J Pain*. 2013;14(4):S62.
- Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised control trial. *Pain*. 2004 Dec;112(3):299-306.
- Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)*. 2006 Jan;45(1):50-52.

- Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: Systematic review of randomized controlled trials. *Can Fam Physician*. 2015;61(8):e372-381.
- Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. *BMJ*. 2008;336(7637):199-201.
- Karst M, Salim K, burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. *JAMA*. 2003;290(13):1757-1762.
- Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. *J Neurol*. 2013;260(4):984-997.
- Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Br J Clin Pharmacol*. 2011;72(5):735-744.
- Martin-Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and meta-analysis of cannabis treatment for chronic pain. *Pain Med*. 2009;10(8):1353-1368.
- Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. *Pain*. 2007;133(1-3):210-220.
- Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology*. 2005;65(6):812-819.
- Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. *Eur J Pain*. 2014;18(7):999-1012.
- Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. *J Pain*. 2008;9(2):164-173.
- Turcotte D, Doupe M, Torabi M, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. *Pain Med*. 2015;16(1):149-159.
- Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ*. 2010;182(14):E694-701.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA*. 2015;313(24):2456-2473.
- Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain*. 2013;14(2):136-148.
- Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain*. 2008;9(6):506-521.

## Acute Pain

- Buggy DJ, toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. *Pain*. 2003 Nov;106(1-2):169-172.
- Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *BMJ*. 2001 Jul;323(7303):13-16.
- Raft D, Gregg J, Ghia J, Harris L. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response. *Clin Pharmacol Ther*. 1977 Jan;21(1):26-33.

## Cannabinoid/Cannabis Opioid Interactions

- Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. *Clin Pharmacol Ther*. 2011;90(6):844-851.
- Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. *Pain*. 2003;105(1-2):79-88.
- Narang S, Gibson D, Wasan AD, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. *J Pain*. 2008;9(3):254-264.
- Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. *J Pain*. 2012;13(5):438-449.

## Nausea and Vomiting

- Machado Rocha FC, Stefano SC, De Cassia Haiek R, Ross Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. *Eur J Cancer Care*. 2008;17(5):431-443.
- Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. *Cochrane Database Syst Rev*. 2015(11).
- Soderpalm AHV, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. *Pharmacol Biochem Behav*. 2001;69(3-4):343-350.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA*. 2015;313(24):2456-2473.

## Appetite and Weight

- AbbVie Inc. Marinol Drug Label Information. 2015. Available from: <http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bbac0b1-ddc2-400b-8e0d-1e1d484720ca>. Accessed on: December 3, 2015.

- Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. *J Clin Oncol.* 2002;20(2):576-573.
- Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Cochrane Database Syst Rev.* 2013;4.
- Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. *J Clin Oncol.* 2006;24(21):3394-3400.
- Timpone JG, Wright FJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. *AIDS Res Hum Retroviruses.* 1997;13(4):305-315.

### **Spasticity and Multiple Sclerosis**

- Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *Eur J Neurol.* 2007;14(3):290-296.
- Corey-Bloom J, Wolfson T, Garnst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ.* 2012;184(10):1143-1150.
- Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. *Mult Scler.* 2010;16(11):1349-1359.
- Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2014;82(17):1556-1563.
- Rog DJ, Murbikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology.* 2005;65(6):812-819.
- Vaney C, Heinzl-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. *Mult Scler.* 2004;10(4):417-424.
- Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Mult Scler.* 2004;10:434-441.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA.* 2015;313(24):2456-2473.
- Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet.*

2003;363(9395):1517-1526.

### Neurological Conditions

- Ahmed A, van der Marck MA, van den Elsen G, Olde Rikkert M. Cannabinoids in late-onset Alzheimer's disease. *Clin Pharmacol Ther.* 2015;97(6):597-606.
- Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. *Neurology.* 2004;63(7):1245-1250.
- Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. *Pharmacol Biochem Behav.* 1991;40(3):701-708.
- Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. *Mov Disord.* 2009;24(15):2254-2259.
- Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. *J Mol Med (Berl).* 2006;84(3):253-258.
- Eubanks LM, Rogers CJ, Beuscher AE 4th, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. *Mol Pharm.* 2006;3(6):773-777.
- Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from *Cannabis sativa*, on beta-amyloid-induced toxicity in PC12 cells. *J Neurochem.* 2004;89(1):134-141.
- Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2014;82(17):1556-1563.
- Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. *Clin Neuropharmacol.* 2014;37(2):41-44.
- Martin-Moreno AM, Reigada D, Ramirez BG, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. *Mol Pharmacol.* 2011;79(6):964-973.
- Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. *Pharmacopsychiatry.* 2002;35(2):57-61.
- Müller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. *J Clin Psychiatry.* 2003;64(4):459-465.
- Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. *J Neurosci.* 2005;25(8):1904-1913.

- Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. *Neurology*. 2001;57(11):2108-2111.

### Seizures

- Ames FR, Cridland JS. The antiemetic effect of Cannabis sativa during cytotoxic therapy. *S Afr Med J*. 1985;68(11):780-781.
- Consroe PF, Sandyk R. Potential role of cannabinoid for therapy of neurological disorders. *In: Marijuana/Cannabinoids Neurobiology and Neurophysiology*. Boca Raton: CRC Press; 1992.
- Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. *Pharmacology*. 1980;21(3):175-185.
- Maa E, Figi P. The case for medical marijuana in epilepsy. *Epilepsia*. 2014;55(6):783-786.
- Mechoulam R, Carlini EA. Toward drugs derived from cannabis. *Naturwissenschaften*. 1978;65(4):174-179.
- Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. *Epilepsy Behav*. 2013;29(3):574-577.
- Tremblay B, Sherman M. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids; 1990 July 8-11; Kolympari, Crete.

### Glaucoma

- Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. *J Glaucoma*. 2006;15(5):349-353.

### Psychiatric Disorders

- Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. *Neuropsychopharmacology*. 2011;36(6):1219-1226.
- Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. *J Psychopharmacol*. 2011;25(1):121-130.
- Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). *CNS Neurosci Ther*. 2009;15(1):84-88.
- Greer GR, Grob CS, Halberstadt AL. PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. *J Psychoactive Drugs*. 2014;46(1):73-77.
- Segev A, Lev-Ran S. Neurocognitive functioning and cannabis use in schizophrenia. *Curr Pharm Des*. 2012;18(32):4999-5007.

- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA*. 2015;313(24):2456-2473.
- Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Effects of ipsapirone and cannabidiol on human experimental anxiety. *J Psychopharmacol*. 1993;7(1 Suppl):82-88.

### **Sleep Disorders**

- Prasad B, Radulovacki MG, Carley DW. Randomized Placebo Controlled Trial Of Dronabinol In Obstructive Sleep Apnea. *Am J Respir Crit Care Med*. 2011;183.
- Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ*. 2010;182(14):E694-701.
- Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA*. 2015;313(24):2456-2473.